Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Yatharth Hospital & Trauma Care Services Ltd

YATHARTH
NSE
802.95
2.86%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Yatharth Hospital & Trauma Care Services Ltd

YATHARTH
NSE
802.95
2.86%
29 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
7,737Cr
Close
Close Price
802.95
Industry
Industry
Hospitals
PE
Price To Earnings
45.31
PS
Price To Sales
7.10
Revenue
Revenue
1,089Cr
Rev Gr TTM
Revenue Growth TTM
31.82%
PAT Gr TTM
PAT Growth TTM
26.83%
Peer Comparison
How does YATHARTH stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
YATHARTH
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
144155171167178212218219232258279320
Growth YoY
Revenue Growth YoY%
39.133.921.323.637.127.131.430.421.728.346.2
Expenses
ExpensesCr
105113126120131158163164175193215246
Operating Profit
Operating ProfitCr
384146464754555557646574
OPM
OPM%
26.826.826.627.826.225.325.125.124.625.023.123.2
Other Income
Other IncomeCr
114564345998
Interest Expense
Interest ExpenseCr
663003221001
Depreciation
DepreciationCr
8778811161713151924
PBT
PBTCr
252940444443404049595557
Tax
TaxCr
810121461391010171414
PAT
PATCr
171928293830313039424143
Growth YoY
PAT Growth YoY%
73.170.438.8121.459.612.13.41.038.433.341.3
NPM
NPM%
12.112.316.117.721.614.314.213.916.716.314.813.4
EPS
EPS
2.62.93.83.84.83.53.63.64.44.44.34.7

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
78861021462294015206718801,089
Growth
Revenue Growth%
11.418.043.456.675.329.828.931.323.7
Expenses
ExpensesCr
606882108162290387491660829
Operating Profit
Operating ProfitCr
1718193867111134180220260
OPM
OPM%
22.421.019.125.729.327.625.726.825.023.9
Other Income
Other IncomeCr
0000123161632
Interest Expense
Interest ExpenseCr
65619192121982
Depreciation
DepreciationCr
76821212828295771
PBT
PBTCr
585-2286388157172219
Tax
TaxCr
221091922424154
PAT
PATCr
364-2204466114131165
Growth
PAT Growth%
96.3-33.2-151.61,054.1125.548.974.114.026.5
NPM
NPM%
3.96.93.9-1.48.611.012.617.114.815.2
EPS
EPS
2.23.80.6-0.22.86.810.114.514.717.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
14161616166666869696
Reserves
ReservesCr
2941393856511177881,5091,592
Current Liabilities
Current LiabilitiesCr
91042605597100678593
Non Current Liabilities
Non Current LiabilitiesCr
8612615616517321220378943
Total Liabilities
Total LiabilitiesCr
1381932572873094264861,0191,7311,856
Current Assets
Current AssetsCr
2028242949109176510856667
Non Current Assets
Non Current AssetsCr
1181652332582593173105098751,189
Total Assets
Total AssetsCr
1381932572873094264861,0191,7311,856

Cash Flow

Consolidated
Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
25171739446064-3150
Investing Cash Flow
Investing Cash FlowCr
-50-51-78-43-21-52-20-226-420
Financing Cash Flow
Financing Cash FlowCr
2643475-19-1-18304520
Net Cash Flow
Net Cash FlowCr
19-131372675249
Free Cash Flow
Free Cash FlowCr
2416-60-4242144-96-161
CFO To PAT
CFO To PAT%
822.5287.0439.1-1,911.0223.0135.797.0-2.7114.6
CFO To EBITDA
CFO To EBITDA%
144.094.589.8104.465.254.147.7-1.767.9

Ratios

Consolidated
Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
00000003,5834,092
Price To Earnings
Price To Earnings
0.00.00.00.00.00.00.031.331.3
Price To Sales
Price To Sales
0.00.00.00.00.00.00.05.34.7
Price To Book
Price To Book
0.00.00.00.00.00.00.04.12.5
EV To EBITDA
EV To EBITDA
4.86.39.05.12.82.31.719.116.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
80.679.880.981.779.779.782.180.179.7
OPM
OPM%
22.421.019.125.729.327.625.726.825.0
NPM
NPM%
3.96.93.9-1.48.611.012.617.114.8
ROCE
ROCE%
8.46.94.96.617.722.224.217.311.1
ROE
ROE%
7.110.57.2-3.827.037.836.013.18.1
ROA
ROA%
2.23.11.6-0.76.310.413.511.27.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** Yatharth Hospital & Trauma Care Services Ltd is one of North India’s leading private healthcare providers, specializing in tertiary and quaternary care. Established in 2008, the company has grown rapidly through a combination of organic expansions and strategic acquisitions, currently operating a network of **seven super-specialty hospitals** with a **total bed capacity of over 2,300 beds**, including **640 critical care beds**. The company is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), having gone public in 2023. Headquartered in the National Capital Region (NCR), Yatharth has built a dominant presence across **Delhi, Noida, Greater Noida, Faridabad, Haryana, and the Jhansi-Orchha region in Madhya Pradesh**, focusing on high-density urban catchments with underserved healthcare infrastructure. --- ### **Recent Strategic Developments (2023–2025)** #### **1. Aggressive Expansion via Acquisitions** Yatharth has significantly expanded its footprint through a series of inorganic growth initiatives: - **Agra Hospital (Nov 2025):** Acquired 100% stake in a 150-bed multi-specialty hospital (expandable to 250 beds) located on **NH-19 in Agra, Uttar Pradesh**, for **Rs. 260 crores**. The 165,000 sq. ft facility is expected to be integrated into the network in **H2 FY26**, contributing to revenue and EBITDA from day one. It serves a large underpenetrated population and will operate as a **standalone super specialty hub**, offering cardiac surgery, angioplasty, and oncology services. - **Earlier Acquisitions:** - **Jhansi-Orchha Hospital (305 beds)** in 2023. - **Agra Hospital (250 beds)** in 2024. - In **2025**, acquired three major facilities: a **200-bed Gr. Faridabad** hospital, a **300-bed Delhi (Model Town)** hospital, and a **400-bed Faridabad (Sector 20)** hospital via a **60% stake acquisition** (enterprise value: **Rs. 152 crores**, payment: **Rs. 91 crores**). These moves position Yatharth as **one of the top 3 hospital chains in North India by bed count**, with a regional concentration that enhances operational synergies. --- ### **Growth Strategy & Capacity Expansion** Yatharth is executing a dual strategy of **brownfield expansion and greenfield development** with the goal of **3,000 beds by FY28**: - **Brownfield Expansions:** - **Greater Noida Hospital:** Expanding from 400 to **600 beds**. - **Noida Extension Hospital:** Expanding from 450 to **700 beds**. - **Greenfield Projects:** - New hospitals in **Delhi Model Town (~300 beds)** and **Faridabad (~400 beds)** are fully registered, possessed, and slated for **Q1 FY26 operationalization**. - **CAPEX per bed:** ~**Rs. 1 crore**, improved through operational efficiencies. The company plans to add **~1,200 new beds over the next three years**, prioritizing **high-growth urban centers** in **Uttar Pradesh, Haryana, Punjab, and Bihar**. --- ### **Clinical Excellence & Technology Adoption** Yatharth is shifting toward **high-acuity, super-specialty care**, driving growth and profitability: - **Revenue Shift:** Super-specialties now dominate, with **oncology contributing 11% of group revenue** and **~19–20% at Noida Extension**. - **Centers of Excellence (COEs)** established in **Cardiology, Neurosciences, Oncology, Orthopaedics, Renal Sciences, Gastroenterology, and Spine Care**. - **Robotic Surgery:** Equipped with **three Da Vinci X Surgical Robots and one Stryker Orthopedic robot**; has completed **over 115 robotic surgeries**. - **Advanced Technology:** Deployed **Rapid AI for stroke diagnosis, PET-CT, brachytherapy, radiation oncology (Elekta Versa HD), CAR-T cell therapy**, and **3DaVinci and Stryker robotic systems**. - **Transplant Services:** Offering **kidney, liver, and bone marrow transplants**; Noida Extension Hospital is a designated **Center of Excellence for organ transplants**. The **Noida Extension Hospital** is the **first in Uttar Pradesh to achieve Joint Commission International (JCI) accreditation**, complementing **NABH/NABL certifications** across all facilities. --- ### **Financial & Operational Performance** - **Revenue Growth:** Achieved **over 30% YoY revenue growth** in FY25, supported by new hospital ramp-ups. - **EBITDA Growth:** Over **20% YoY growth**, with strong operating cash flows of **INR 1,496 million** in FY25 and a **70% cash conversion ratio**. - **Occupancy & ARPOB:** - Group-wide occupancy improved to **61% in H1 FY25 (from 54% in H1 FY24)**. - **Average Revenue Per Occupied Bed (ARPOB)** reached **₹38,033 at Noida Extension**, ₹30,721 at Greater Faridabad. - Strategic shift to **lower government scheme reliance** in new facilities improves revenue quality. --- ### **Medical Value Travel (MVT) / International Expansion** Yatharth is developing **MVT as a second growth engine**, leveraging the upcoming **Jewar International Airport** (Asia’s largest): - **Representative Offices:** Established in **Tashkent** and **Baghdad** to serve as MVT hubs for **CIS and West Asia**. - **Information Centers:** Planned in **Tajikistan, Mauritius, Tanzania, and Kenya**. - **Outreach:** Conducted **health camps and OPDs** in **Nigeria, Iraq, Uzbekistan, and CIS countries**. - **Target Regions:** Nigeria, Cameroon, Ethiopia, Mauritius, Uzbekistan, Tajikistan, and Iraq. - **Dedicated Infrastructure:** - **200 beds at Greater Noida** for international patients. - **International patient floor and lounge** at Noida Extension. - Plans to operate a **clinical examination room at Jewar Airport**. The company aims to become the **exclusive healthcare partner** for the Jewar Airport, enhancing visibility and patient inflows. --- ### **Funding & Investor Confidence** - Raised **Rs. 6,250 million** via a **Qualified Institutional Placement (QIP) in Dec 2024**, signaling investor confidence. - Proceeds allocated to: - **Medical Equipment (Rs. 2,174 crore)** - **Funding Acquisitions (Rs. 1,517 crore)** - **Debt Repayment (Rs. 957 crore)** - The strong balance sheet supports future **acquisitions and CAPEX investments**. --- ### **Market Position & Competitive Advantage** - **Geographic Concentration:** Six of seven hospitals in **core NCR urban centers**, enabling shared services, referrals, and branding. - **High-Density Catchment:** Serves patients from **UP, Delhi, Haryana, Uttarakhand, and neighboring states**. - **Differentiation:** Focus on **world-class infrastructure, technology, and talent**, with a **low doctor attrition rate** due to a supportive professional environment. - **Talent Acquisition:** Recruits senior clinicians (‘number twos’) from Apollo, Max, and Fortis, offering leadership roles in new facilities. - **DNB Residency Program:** Runs across **13 specialties** with ~60 residents, building a future pipeline of super-specialists.